Inizio Engage has launched Connected Insights, an expansion of its Global Medical Information business that’s trying to change what that function is actually for. Medical Information teams have traditionally existed to answer inbound questions from healthcare professionals and patients. Inizio’s pitch is that all those individual interactions, handled well, add up to something much more valuable: a live read on what’s happening across a company’s entire portfolio.
From Answering Questions to Reading Trends
The problem Inizio is pointing to is a familiar one in pharma. As therapies get more specialized and the science gets harder to explain, Medical Information teams are fielding more complex questions than ever, but most organizations still treat that function as a compliance-driven support desk rather than a source of intelligence. Connected Insights is built to convert those individual interactions into portfolio-wide insight, things like emerging trends, unmet needs among healthcare professionals and patients, and signals that can actually shape Medical Affairs strategy, without losing the accuracy and compliance rigor the function depends on.
To get there, the offering leans on a handful of AI-driven tools: AI-powered training personas that Inizio says have driven a tenfold increase in training simulations, speech analytics, virtual agents and agent-assist tools, and what the company calls “Voice of the Agent” capabilities, alongside AI-enabled learning tools that it credits with a 50% improvement in training success rates.
The Scale Behind the Launch
Inizio Engage isn’t a small operation to be layering this onto. The Global Medical Information business handles more than a million interactions a year, spans 500-plus products across 55-plus global programs, and operates in more than 20 languages. That scale is really the point of Connected Insights: individual conversations are only useful as strategic intelligence if you can aggregate and translate patterns across that many markets and languages at once.
Jenny Reid-Young, Vice President of Global Medical Information at Inizio Engage, described the underlying opportunity this way: “Medical Information has become one of the richest sources of scientific insight across the product lifecycle. Organizations that can connect those interactions across markets and translate them into meaningful intelligence will make better decisions, improve customer experiences and strengthen Medical Affairs strategy.”
Amy Van Sant, Global President of Medical Affairs at Inizio Engage, tied it back to the company’s broader positioning: “By combining scientific expertise with AI-enabled capabilities and global scale, we’re helping clients unlock significantly more value from every interaction and redefine what’s possible through Global Medical Information.”
These moves build on Inizio’s ongoing push around Intelligent Commercialization™ — pairing scientific know-how with technology and data insight to help life sciences companies make sharper decisions, deepen engagement, and improve outcomes across the product lifecycle.
Why It’s Worth Noting
This reflects a broader shift across pharma services, where functions once viewed as pure cost centers — including Medical Information , are being reimagined as strategic data sources that inform commercial and R&D decision-making. The opportunity is becoming increasingly clear: service providers that can demonstrate how they transform routine interactions into actionable insights, rather than simply delivering accurate responses, are positioning themselves as more valuable and harder to replace.
